SCHEMBL3635557

SCHEMBL3635557

COc1ccccc1C(C(=O)NNc1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCN(C)CC1

nearest known ligand 0.77

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 2/20 0.77
TACR1 P25103 11/20 0.48
CCR3 P51677 1/20 0.47
GAA P10253 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
SLC6A9 P48067 2/20 0.39
HTR1A P08908 2/20 0.38
HTR1D P28221 2/20 0.38
HTR1B P28222 2/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR6 P50406 2/20 0.38
HTR7 P34969 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3635203 0.92 GHSR (0.74) GHSRTACR1CCR3RXFP1
SCHEMBL13078455 0.92 GHSR (0.66) GHSRTACR1CCR3
SCHEMBL3639164 0.88 GHSR (0.80) GHSRTACR1CCR3
SCHEMBL3638153 0.88 GHSR (0.80) GHSRTACR1
SCHEMBL3640188 0.87 GHSR (1.00) GHSRTACR1CCR3HTR2A
SCHEMBL3634142 0.87 GHSR (0.61) GHSRTACR1CCR3RXFP1HTR1A
Hydrochloric Acid SCHEMBL3740772 0.86 GHSR (0.98) GHSRTACR1CCR3HTR2A
Hydrochloric Acid SCHEMBL3636980 0.84 GHSR (0.74) GHSRTACR1GAARXFP1HTR1A
SCHEMBL3639974 0.84 GHSR (0.74) GHSRTACR1
SCHEMBL3750300 0.83 GHSR (0.66) GHSRTACR1CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US claimed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP claimed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO claimed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2010-11-11 US disclosed
EP-2167466-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR Glaxo Group Limited (GB) 2010-03-31 EP disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed
WO-2008148853-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GLAXO GROUP LIMITED (GB) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286152-A1 N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR GIPR, GHSR, GLP1R GHSR 2/4885TACR1 56/4885CCR3 3769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.